Source - SMW
ImmuPharma is on track to report top line results from its 52-week, randomised, double-blinded, phase III clinical trial of Lupuzor, its lead programme for the potential breakthrough compound for Lupus.

It said all 200 patients in the study had now passed the nine month stage and 116 (58%) had completed the full 12 months of the study.

Chairman Tim McCarthy  said:  'The trial continues to progress on track and on time.

'Most importantly, we continue to see robust safety within the study which is as equally important as the efficacy profile, in order for Lupuzor to be proactively prescribed by specialists to Lupus patients, who urgently require a more effective treatment for their condition.

'We look forward with confidence to reporting top line results of the study in Q1 2018.'
 
     


At 9:07am: (LON:IMM) ImmuPharma PLC share price was +1.38p at 96.88p



Related Charts

ImmuPharma (IMM)

0.00 (0.00%)
delayed 17:30PM